VISUPLAN 500: ZEISS complements basic diagnostics portfolio for glaucoma screening with non-contact tonometer

JENA, 16.06.2014.

ZEISS strives to serve doctors with complete solutions to support better workflows with the introduction of the non-contact tonometer VISUPLAN® 500. Made with ease of use in mind it assists in identifying patients with high intraocular pressure early in the practice workflow.

Non-contact tonometers enable doctors to examine the patient’s eye without anesthetics or fluorescein based on the air-puff principle. The technology is used to identify patients with high intraocular pressure and a corresponding risk for glaucoma. It complements the current gold standard in tonometry: applanation after Goldmann.

Another benefit for the physicians is that the measurement can be done by practice and clinical staff as part of the general pre-test very early in the practice workflow. VISUPLAN 500 from ZEISS facilitates the delegation with its intuitive user interface with one-button touch screen operation and automatic alignment functions making measurements user independent.

“Since many years we have been a trusted partner for physicians looking for advanced diagnosis and treatment devices offering them complete solutions for optimal workflows. With our non-contact tonometer we round of our offering to ophthalmologists but also other eye care specialists, says Dr. Ludwin Monz, President and CEO of Carl Zeiss Meditec AG.

Brief profile

Carl Zeiss Meditec AG (ISIN: DE 0005313704), which is listed on TecDAX of the German stock exchange, is one of the world’s leading medical technology companies. The Company supplies innovative technologies and application-oriented solutions designed to help doctors improve the quality of life of their patients. It provides complete packages of solutions for the diagnosis and treatment of eye diseases - including implants and consumable materials. The company creates innovative visualisation solutions in the field of microsurgery. The medical technology portfolio of Carl Zeiss Meditec is rounded off by promising, future-oriented technologies such as intraoperative radiotherapy. In financial year 2012/2013 (ended 30 September) the Group's more than 2,500 employees generated revenue of almost € 906 million.

The head office of Carl Zeiss Meditec is in Jena, Germany. The company has subsidiaries in Germany and abroad; more than 50 percent of its employees are based in the USA, Japan, Spain and France. The Center for Research and Development (CARIn) in Bangalore, India and the Carl Zeiss Innovations Center for Research and Development in Shanghai, China, strengthen the presence in these rapidly developing economies. Around 35 percent of Carl Zeiss Meditec shares are in free float. The remaining approx. 65 percent are held by Carl Zeiss AG, one of the world’s leading groups in the optical and optoelectronic industries. Carl Zeiss offers innovative solutions for the future-oriented markets of Medical and Research Solutions, Industrial Solutions, Eye Care and Lifestyle Products. Carl Zeiss AG, Oberkochen, is fully owned by the Carl Zeiss Foundation.